Osteoporosis Ahmed Shaman Department of Clinical Pharmacy

Slides:



Advertisements
Similar presentations
Osteoporosis Wang Ying Department of Rehabilitation Medicine Renji Hospital, Jiaotong University.
Advertisements

WHO Osteoporosis Definition (1996)
Dr. Zhao TCM Help Osteoporosis!
Osteoporosis By Lacie and Janay.
An Inpatient Topic? July 2006
King Abdul Aziz University Faculty Of Pharmacy
Dr santosh kumar Assistant professor Medical unit 2.
Bones, Calcium, and Osteoporosis. Bone Bone is living, constantly remodeled Reservoir of Calcium – Calcium levels of blood take precedence over bone levels.
Osteoporosis Dr. Lauren Phillips Sugar Land Women’s Health.
Osteoporosis UBC Internal Medicine Program Dr. Mark Fok Dr. Maria Ashley.
Bone Mineral Density Testing March 29, Introduction Osteoporosis is a systemic skeletal disorder characterized by decreased bone mass and deterioration.
UNDERSTANDING OSTEOPOROSIS Stephen L. Kates, MD Hansj ӧ rg Wyss Professor of Orthopaedic Surgery Department of Orthopedics and Rehabilitation Associate.
Osteoporosis Osteoporosis is defined as a loss of bone mass or bone mineral density characterized by height reduction, fractures, back/neck pain, and stooped.
Treatment. Bisphosphonates Promotes bone formation and decreases bone resorption Mechanism of Action First line treatment for osteoporosis in both men.
COMMONWEALTH OF AUSTRALIA Copyright Regulations 1969 WARNING This material has been copied and communicated to you by or on behalf of the University of.
Osteoporosis Rajesh Kataria, D.O. Southern Ohio Rheumatology.
Osteoporosis. Introduction Osteoporosis is “a disease of the bones that happens when you lose too much bone, make too little bone, or both.” - National.
Osteoporosis Rajesh Kataria, D.O.. Osteoporosis “…is a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of.
OSTEOPOROSIS Prof. Dr. Ülkü Akarırmak. Metabolic Bone Diseases Osteosclerosis Osteolysis Osteoporosis is the most common metabolic bone disease.
Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c.
Osteoporosis. What is it? Systemic skeletal disease characterised by: –low bone mass –microarchitectural deterioration of bone tissue –resultant increase.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 75 Drugs Affecting Calcium Levels and Bone Mineralization.
OSTEOPOROSIS 06/25/12 José L. González, PGY3. Definition  Reduction in bone strength  increase risk of fx  T-score: < -2.5 SDs  T-score: 30 yo, matched.
Osteoporosis and Fractures Are Common, and Becoming More So
Quiz of the week. 23 years old male patent who presented with sudden onset of sever back pain and his MRI of spine shows a fracture. How do you approach.
DRUGS THAT AFFECT BONE MINERAL HOMEOSTASIS
Copyright © 2011, 2007 by Mosby, Inc., an affiliate of Elsevier Inc.
Clinical manifestations and diagnosis of osteoporosis.
1 Ipriflavone in the Treatment of Postmenopausal Osteoporosis Randomized placebo-controlled, 4-year study conducted Europe 475 postmenopausal white women,
1 Osteoporosis J.B. Handler, M.D. Physician Assistant Program University of New England.
Osteoporosis Dr. Faik Altıntaş Yeditepe Üniversitesi Tıp Fakültesi
Osteoporosis: Review of the Clinical Practice Guidelines Ambulatory Internal Medicine Group Practice Seminar Series October 2007 Lianne Tile MD MEd FRCPC.
Osteoporosis.
By Siraya Kitiyodom ปัญหาที่เกี่ยวกับสุขภาพ ที่พบบ่อยในสตรีวัยทอง และวิธีการดูแล (Part II)
Medication Options H ealthPLACE/HOPE Program COPYRIGHT © 2002 Highmark Inc. All Rights Reserved. These materials may not be copied or otherwise reproduced.
Osteoporosis. Background ► The problem  Osteoporosis is common  Over 50% of women and 30-45% of men over age 50 have osteopenia/osteoporosis  White.
FDA’s Osteoporosis Guidance Center for Drug Evaluation and Research Division of Metabolic and Endocrine Drugs Eric Colman, MD September 25, 2002.
Osteoporosis Dr Ramin Rafiei Alzahra Hospital Rheumatology Department.
Alimohammad Fatemi Assistant Professor of Rheumatology 1.
 Glucocorticoids  Excessive thyroid hormone  Diuretics: Furosemide  Cyclosporine, methotrexate, tacrolimus  Seizure medications: Phenytoin, phenobarbital.
Prevention and Treatment of Osteoporosis
Definition Definition Osteoporosis:A condition of skeletal fragility characterized by reduced bone mass and microarchitectural deterioration of.
Welcome To Our Presentation
OSTEOPOROSIS. Characteristics of osteoporosis include a reduction of bone density and a change in bone structure, both of which increase susceptibility.
Osteopenia and Osteoporosis Bradley K. Harrison, MD.
NICE, FRAX & NOGG VTS meeting Jonathan Day 7 th April 2010.
Moji Saberin-Williams, M.D. Paoli Hospital Obstetrician/Gynecologist
Are your bones healthy? Normal boneOsteoporosis Definition A systemic skeletal disease characterized by low bone mass and micro architectural deterioration.
Chapter ?? 23 Osteoporosis Nichols and Pavlovic C H A P T E R.
 Osteoporosis means "porous bones," causes bones to become weak and brittle – so brittle that even mild stresses like bending over, lifting a vacuum.
Osteoporosis Vinod Kurup, MD December 22nd, 2006 CC-BY-SA.
Osteoporosis. Background Osteoporosis is disorders of the bone, characterized by progressive loss of bone mass and skeletal fragility. Patients with osteoporosis.
Osteoporosis.
Management of Osteoporosis
Osteoporosis هشاشة العظام Dr.Fakhir Yousif.
Drugs Affecting Calcium Levels and Bone Mineralization
Osteoporosis in thalassemia patients
Drugs for osteoporosis (download the lecture from
Medication for osteoporosis
Osteoporosis and drugs used in bone disorders
Post Menopausal Osteoporosis
Osteoprosis Haya M. Al-Malaq, Msc Lecturer
بنـام خـدا.
Osteoporosis Definition
Chapter Drugs used for the treatment of osteoporosis
Pharmacology of parathyroid hormone, vitamin D and calcitonin
Lecture 6 Rheumatologic Disorders Osteoporosis
(Relates to Chapter 64, “Focous on osteoperosis ,” in the textbook)
Consultant Rheumatologist Imperial College Healthcare
Presentation transcript:

Osteoporosis Ahmed Shaman Department of Clinical Pharmacy

Background Reading & References Drugs for Postmenopausal Osteoporosis. Treatment Guidelines from The Medical Letter 2008:6(74); Sundeep Khosla, M.D., and L. Joseph Melton III, M.D., M.P.H. Osteopenia. N Engl J Med 2007;356: Dipiro Chapter 93

Introduction Osteoporosis is a common and often silent disorder causing significant morbidity and mortality and reduced quality of life It is associated with increased risk and rate of bone fracture Common sites of fracture include the spine, hip, and wrist The fractures associated with osteoporosis have an enormous impact on individual patients Acute pain Chronic pain Loss of mobility Height loss Depression Nursing home placement Death

Physiology & pharmacology of bone formation

Bone Mineral Density

Measurement of Bone Mineral Density Bone mineral density can be measured at various sites throughout the skeletal system Central (hip and/or spine) Peripheral (heel, forearm, or hand) Various methods Dual-energy x-ray absorptiometry (DXA) central and peripheral sites Quantitative ultrasound Peripheral quantitative computed tomography Radiographic absorptiometry Single-energy x-ray absorptiometry Central DXA is recommended for diagnosis due to inconsistencies in T-scores measured between different sites and by different methods Peripheral sites

Interpreting BMD Data T-scores and Z-scores are used T-score is the number of standard deviations from the mean bone mineral density in healthy young white women The Z-score is a similar measure that is corrected for age and gender of the patient Skeletal DisordersT-scores Normal≥ -1 OsteopeniaBetween -2.5 and -1.0 Osteoporosis< -2.5

Clinical Presentation and Diagnosis of Osteoporosis General Many patients with osteoporosis are asymptomatic unless they experience a fragility fracture Symptoms Symptoms of fragility fracture include pain at the site of the fracture or immobility Signs Height loss (greater than 2 cm) Spinal kyphosis (“dowager’s hump”) Fragility fracture especially of the hip or spine Laboratory Tests Lab tests are only useful to rule out secondary causes of osteoporosis Diagnostic Tests Bone densitometry using DXA reveals a T-score at least -2.5 SD below the mean

Laboratory Evaluation Identifying or excluding secondary causes Hyperparathyroidism Low 25-hydroxyvitamin D levels Hyperthyroidism Cancer

TREATMENT Pharmacologic and nonpharmacologic therapies are aimed at: 1.Preventing fractures and their complications 2.Maintaining or increasing bone mineral density 3.Preventing secondary causes of bone loss 4.Reducing morbidity and mortality associated with osteoporosis

Treatment Lifestyle modification Calcium Vitamin D Bisphosphonates Alendronate Risedronate Ibandronate Zoledronic Acid

Treatment (2) Hormonal Therapy Raloxifene Estrogen Calcitonin Parathyroid Hormone Testosterone in some men

Lifestyle Modification

Drugs Causing Fall Medications associated with increased risk of falling Drugs affecting mental status antipsychotics, benzodiazepines, tricyclic antidepressants, sedative/hypnotics, anticholinergics, and corticosteroids Drugs causing orthostatic hypotension Some cardiovascular and antihypertensive

Calcium & Vitamin D Elderly patients or patients receiving proton pump inhibitors or H2-receptor antagonists may have added difficulty absorbing calcium supplements due to reduced stomach acidity→ Ca citrate or Ca acetate more soluble Over 65 yearsAdults under 65 years Calcium1,500 mg / day1,000 mg / day Vitamin D800 – 1,000 IU / day400 – 800 IU / day

Calcium Adverse Events Constipation, bloating, cramps, and flatulence Changing to a different salt form may alleviate symptoms for some patients Calcium salts may reduce the absorption of Iron Some antibiotics, such as tetracycline and fluoroquinolones (up to 50%) Thyroid hormone → separate time of administration

Bisphosphonates Bisphosphonates are first-line therapy for osteoporosis due to established efficacy in preventing hip and vertebral fractures Decrease bone resorption by binding active sites & inhibiting osteoclasts IV & PO formulations

Bisphosphonates

Bisphosphonates – Adverse Effects Oral: heartburn, esophageal irritation & esophagitis. Must take with about 180–240 mL of water after overnight fast & in upright position Afterwards stay upright minutes & don’t take anything by mouth except water IV: infusion reactions, atrial arrhythmias Either (especially IV & with chronic use) Osteonecrosis of the jaw Risk factors include Chemotherapy, radiotherapy, corticosteroids, infection or pre- existing dental disease

Bisphosphonates Bisphosphonates are not recommended for use in patients with esophageal abnormalities, hypocalcaemia, renal insufficiency or failure (creatinine clearance less than 30–35 mL/min) Bisphosphonates should not be taken with other medications or dietary supplements(↓absorption)

Bisphosphonates

Hormones Raloxifene: Selective estrogen receptor modulator (SERM) Estrogen-like effects on bone (reduce bone resorption and decrease overall bone turnover) Prevents & treats osteoporosis, ↓ vertebral fractures by 30% AE: Hot flashes, leg cramps & edema Increase risk of thrombosis Increase risk of fatal stroke

Hormones Estrogen (HRT) Replacement in postmenopausal women Prevents hip and veterbral fractures by 33% Give with progestin if intact uterus to prevent endometrial cancer No longer recommended due to adverse effects Increase risk of cardiac death, MI, stroke, pulmonary embolism & breast cancer WHI and HERS studies

Other Pharmacotherapy Calcitonin Inhibits osteoclasts IM, SC (neutralizing antibodies) and intranasal Treatment; causes nasal irritation AEs including flushing, urinary frequency, nausea, vomiting, abdominal cramping, and irritation at the injection site Teriparatide Parathyroid Hormone, stimulates bone formation Risk of hypercalcemia, orthostatisc hypotention Treatment; black box warning for osteosarcoma

Treatment Overview For everyone Calcium, Vitamin D Osteopenia (T score – 1.0 to 2.49) Add Lifestyle Modification Consider pharmacotherapy risk vs benefit Osteoperosis (T score or more) or fracture Add pharmacotherapy (likely bisphosphonate)